You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ORR

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Objective Response Rate (ORR) Trial (Envafolimab, Lenvatinib Combined With TACE)

Not yet recruiting
  • Objective Response Rate (ORR)
  • Envafolimab, Lenvatinib Combined With TACE
  • (no location specified)
Oct 13, 2022

Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Resin microspheres containing yttrium-90 (Y-90)
  • Mission Hills, California
  • +15 more
Sep 15, 2022

Suicide Trial in Chicago (Robinson's Culturally Adapted Coping with Stress Course (A-CWS), Standard Care Control Condition)

Recruiting
  • Suicide
  • Robinson's Culturally Adapted Coping with Stress Course (A-CWS)
  • Standard Care Control Condition
  • Chicago, Illinois
  • +3 more
Apr 8, 2022

Anxiety Disorders Trial in Stony Brook (Project EMPOWER, Online Resources and Referrals)

Completed
  • Anxiety Disorders
  • Project EMPOWER
  • Online Resources and Referrals
  • Stony Brook, New York
    Stony Brook University
Mar 15, 2021

Rheumatoid Arthritis Trial in Worldwide (PF-06650833, PF-06651600, Tofacitinib)

Completed
  • Rheumatoid Arthritis
  • Pleven, Bulgaria
  • +143 more
Mar 2, 2022

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023

Colorectal Cancer, Liver Metastases, MSS Trial (Sinti+Rego+Cele)

Not yet recruiting
  • Colorectal Cancer
  • +2 more
  • (no location specified)
Jul 3, 2023

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Recruiting
  • Multiple Myeloma
    • Annecy, France
    • +19 more
    Sep 28, 2023

    Metastatic Solid Tumor Trial in Worldwide (Sacituzumab Govitecan-hziy)

    Recruiting
    • Metastatic Solid Tumor
    • Sacituzumab Govitecan-hziy
    • Anchorage, Alaska
    • +64 more
    Jan 23, 2023

    Fibrolamellar Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, DRP-104)

    Not yet recruiting
    • Fibrolamellar Hepatocellular Carcinoma
    • Baltimore, Maryland
      Johns Hopkins SKCCC
    Aug 30, 2023

    Advanced NSCLC Trial (BNT116, Cemiplimab)

    Not yet recruiting
    • Advanced Non-Small Cell Lung Cancer
    • (no location specified)
    Jan 3, 2023

    Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

    Not yet recruiting
    • Relapsed/Refractory Waldenstrom Macroglobulinemia
    • +3 more
    • Brexucabtagene Autoleucel
    • +2 more
    • (no location specified)
    Sep 8, 2022

    Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

    Recruiting
    • Premenopausal Breast Cancer
    • +2 more
    • Taipei City, Taiwan
      Department of Oncology, National Taiwan University Hospital
    Feb 7, 2023

    Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

    Not yet recruiting
    • Breast Cancer
    • Metastatic Breast Cancer
    • Trastuzumab-Deruxtecan (T-DXd)
    • (no location specified)
    Sep 20, 2023

    Advanced Lung Cancer, Ovarian Cancer Trial in Changsha, Yangzhou, Shanghai (AL2846 capsule)

    Recruiting
    • Advanced Lung Cancer
    • Ovarian Cancer
    • AL2846 capsule
    • Changsha, Hunan, China
    • +3 more
    Apr 4, 2023

    NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

    Recruiting
    • NSCLC
    • EGFR Gene Mutation
    • neo-antigen vaccine
    • Nanjing, China
      The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
    Oct 19, 2023

    Peripheral Blood Neoantigen Specific T Cells Predict Efficacy of

    Recruiting
    • Esophageal Squamous Cell Carcinoma
      • Shanghai, Shanghai, China
        Cancer hospital Fudan University
      Nov 30, 2022

      Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)

      Recruiting
      • Neuroblastoma
      • Ganglioneuroblastoma
      • monoclonal antibodies GD2
      • Moscow, Russian Federation
        Research Institute of Pediatric Hematology, Oncology and Immunol
      Oct 4, 2023

      Patients With Relapsed/Refractory Multiple Myeloma

      Not yet recruiting
      • Relapsed and Refractory Multiple Myeloma (RRMM)
      • Non-Interventional
      • (no location specified)
      Dec 21, 2022

      Differentiated Thyroid Cancer Trial in China (AL2846 capsule)

      Recruiting
      • Differentiated Thyroid Cancer
      • AL2846 capsule
      • Guilin, Guangxi, China
      • +3 more
      Feb 27, 2023

      Squamous Cell Carcinoma Trial (MK-3475A)

      Not yet recruiting
      • Squamous Cell Carcinoma
      • MK-3475A
      • (no location specified)
      Sep 11, 2023

      Multiple Myeloma Trial in Canton (Lenalidomide)

      Recruiting
      • Multiple Myeloma
      • Canton, Ohio
        Gabrail Cancer & Research Center
      Oct 11, 2023

      Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

      Recruiting
      • Relapsed/Refractory Peripheral T-cell Lymphoma
      • Aurora, Colorado
      • +2 more
      Jan 3, 2023

      Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

      Not yet recruiting
      • Solid Tumor
      • +2 more
      • favezelimab/pembrolizumab
      • +2 more
      • (no location specified)
      Sep 7, 2023

      Cancer of Pancreas Trial in Dallas (Bemcentinib, Nab-paclitaxel, Gemcitabine)

      Terminated
      • Cancer of Pancreas
      • Dallas, Texas
        University of Texas Southwestern Medical Center
      Sep 26, 2022